T2 Biosystems to Present at the Cantor Fitzgerald Global Healthcare Conference

LEXINGTON, Mass., Sept. 18, 2017 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, today announced that John McDonough, president and chief executive officer, and Darlene Deptula-Hicks, SVP and chief financial officer, are scheduled to attend and present at the Cantor Fitzgerald Global Healthcare Conference. The conference is being held September 25-27, 2017 at the InterContinental New York Barclay Hotel in New York City.

Management is scheduled to present on Monday, September 25, 2017 at 10:55 a.m. ET and will be available for one-on-one meetings during the conference.  The presentation will be webcast live and available for replay and may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at www.t2biosystems.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days following the presentation.

About T2 Biosystems
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis Solution^TM is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems’ products, including the T2Dx^® Instrument and T2Candida^® Panel, and the T2Bacteria^® Panel, which is commercially available in Europe and other countries that accept the CE mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR^®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
[email protected] 
603-553-5803

Media Contact:
Amy Phillips, Feinstein Kean Healthcare
[email protected] 
412-327-9499

Investor Contact:
Chris Brinzey, Westwicke Partners 
[email protected] 
339-970-2843